162 related articles for article (PubMed ID: 28376212)
1. Durable Control of Metastatic AKT1-Mutant WHO Grade 1 Meningothelial Meningioma by the AKT Inhibitor, AZD5363.
Weller M; Roth P; Sahm F; Burghardt I; Schuknecht B; Rushing EJ; Regli L; Lindemann JP; von Deimling A
J Natl Cancer Inst; 2017 Mar; 109(3):1-4. PubMed ID: 28376212
[TBL] [Abstract][Full Text] [Related]
2. AKT1
John P; Waldt N; Liebich J; Kesseler C; Schnabel S; Angenstein F; Sandalcioglu IE; Scherlach C; Sahm F; Kirches E; Mawrin C
Neuropathol Appl Neurobiol; 2022 Feb; 48(2):e12780. PubMed ID: 34837233
[TBL] [Abstract][Full Text] [Related]
3. AKT1E17K mutations cluster with meningothelial and transitional meningiomas and can be detected by SFRP1 immunohistochemistry.
Sahm F; Bissel J; Koelsche C; Schweizer L; Capper D; Reuss D; Böhmer K; Lass U; Göck T; Kalis K; Meyer J; Habel A; Brehmer S; Mittelbronn M; Jones DT; Schittenhelm J; Urbschat S; Ketter R; Heim S; Mawrin C; Hainfellner JA; Berghoff AS; Preusser M; Becker A; Herold-Mende C; Unterberg A; Hartmann C; Kickingereder P; Collins VP; Pfister SM; von Deimling A
Acta Neuropathol; 2013 Nov; 126(5):757-62. PubMed ID: 24096618
[TBL] [Abstract][Full Text] [Related]
4. The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere.
Li J; Davies BR; Han S; Zhou M; Bai Y; Zhang J; Xu Y; Tang L; Wang H; Liu YJ; Yin X; Ji Q; Yu DH
J Transl Med; 2013 Oct; 11():241. PubMed ID: 24088382
[TBL] [Abstract][Full Text] [Related]
5. AKT Inhibition in Solid Tumors With AKT1 Mutations.
Hyman DM; Smyth LM; Donoghue MTA; Westin SN; Bedard PL; Dean EJ; Bando H; El-Khoueiry AB; Pérez-Fidalgo JA; Mita A; Schellens JHM; Chang MT; Reichel JB; Bouvier N; Selcuklu SD; Soumerai TE; Torrisi J; Erinjeri JP; Ambrose H; Barrett JC; Dougherty B; Foxley A; Lindemann JPO; McEwen R; Pass M; Schiavon G; Berger MF; Chandarlapaty S; Solit DB; Banerji U; Baselga J; Taylor BS
J Clin Oncol; 2017 Jul; 35(20):2251-2259. PubMed ID: 28489509
[TBL] [Abstract][Full Text] [Related]
6. Targeting Mutant AKT in Cancer.
Cancer Discov; 2016 Jan; 6(1):OF7. PubMed ID: 26577299
[TBL] [Abstract][Full Text] [Related]
7. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors.
Davies BR; Guan N; Logie A; Crafter C; Hanson L; Jacobs V; James N; Dudley P; Jacques K; Ladd B; D'Cruz CM; Zinda M; Lindemann J; Kodaira M; Tamura K; Jenkins EL
Mol Cancer Ther; 2015 Nov; 14(11):2441-51. PubMed ID: 26351323
[TBL] [Abstract][Full Text] [Related]
8. Visceral and bone metastases of a WHO grade 2 meningioma: A case report and review of the literature.
Paix A; Waissi W; Antoni D; Adeduntan R; Noël G
Cancer Radiother; 2017 Feb; 21(1):55-59. PubMed ID: 28237610
[TBL] [Abstract][Full Text] [Related]
9. SMO mutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomas.
Boetto J; Bielle F; Sanson M; Peyre M; Kalamarides M
Neuro Oncol; 2017 Mar; 19(3):345-351. PubMed ID: 28082415
[TBL] [Abstract][Full Text] [Related]
10. Frequent AKT1E17K mutations in skull base meningiomas are associated with mTOR and ERK1/2 activation and reduced time to tumor recurrence.
Yesilöz Ü; Kirches E; Hartmann C; Scholz J; Kropf S; Sahm F; Nakamura M; Mawrin C
Neuro Oncol; 2017 Aug; 19(8):1088-1096. PubMed ID: 28482067
[TBL] [Abstract][Full Text] [Related]
11. Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea.
Schrell UM; Rittig MG; Anders M; Koch UH; Marschalek R; Kiesewetter F; Fahlbusch R
J Neurosurg; 1997 May; 86(5):840-4. PubMed ID: 9126900
[TBL] [Abstract][Full Text] [Related]
12. Metastatic rhabdoid meningioma with BRAF V600E mutation and good response to personalized therapy: case report and review of the literature.
Mordechai O; Postovsky S; Vlodavsky E; Eran A; Constantini S; Dotan E; Cagnano E; Weyl-Ben-Arush M
Pediatr Hematol Oncol; 2015 Apr; 32(3):207-11. PubMed ID: 25116269
[TBL] [Abstract][Full Text] [Related]
13. Genetic landscape of meningioma.
Yuzawa S; Nishihara H; Tanaka S
Brain Tumor Pathol; 2016 Oct; 33(4):237-247. PubMed ID: 27624470
[TBL] [Abstract][Full Text] [Related]
14. Medical management of meningiomas.
Chukwueke UN; Wen PY
Handb Clin Neurol; 2020; 170():291-302. PubMed ID: 32586501
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma.
Abedalthagafi M; Bi WL; Aizer AA; Merrill PH; Brewster R; Agarwalla PK; Listewnik ML; Dias-Santagata D; Thorner AR; Van Hummelen P; Brastianos PK; Reardon DA; Wen PY; Al-Mefty O; Ramkissoon SH; Folkerth RD; Ligon KL; Ligon AH; Alexander BM; Dunn IF; Beroukhim R; Santagata S
Neuro Oncol; 2016 May; 18(5):649-55. PubMed ID: 26826201
[TBL] [Abstract][Full Text] [Related]
16. Everolimus effectively blocks pulmonary metastases from meningioma.
Bertolini F; Pecchi A; Stefani A; Fontana A; Rossi G
Neuro Oncol; 2015 Sep; 17(9):1301-2. PubMed ID: 26293327
[No Abstract] [Full Text] [Related]
17. Fibroblast growth factor receptor-3 expression in meningiomas with stimulation of proliferation by the phosphoinositide 3 kinase-Akt pathway.
Johnson MD; O'Connell MJ; Pilcher W; Reeder JE
J Neurosurg; 2010 May; 112(5):934-9. PubMed ID: 19698046
[TBL] [Abstract][Full Text] [Related]
18. A gain of function mutation in AKT1 increases hexokinase 2 and diminishes oxidative stress in meningioma.
Singh S; Lathoria K; Umdor SB; Singh J; Suri V; Sen E
Cytokine; 2024 Apr; 176():156535. PubMed ID: 38325141
[TBL] [Abstract][Full Text] [Related]
19. Somatic AKT1 mutations cause meningiomas colocalizing with a characteristic pattern of cranial hyperostosis.
Keppler-Noreuil KM; Baker EH; Sapp JC; Lindhurst MJ; Biesecker LG
Am J Med Genet A; 2016 Oct; 170(10):2605-10. PubMed ID: 27550858
[TBL] [Abstract][Full Text] [Related]
20. Cucurbitacin I blocks cerebrospinal fluid and platelet derived growth factor-BB stimulation of leptomeningeal and meningioma DNA synthesis.
Johnson MD; O'Connell MJ; Walter K
BMC Complement Altern Med; 2013 Nov; 13():303. PubMed ID: 24188277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
